References
- Landgren O, Thomas A, Mailankody S. Myeloma and second primary cancers. N Engl J Med. 2011;365:2241–2242.
- Kotchetkov R, Mashih-Khan E, Chu CM, et al. Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients. Cancer Med. 2017;6:3–11.
- Dimopoulos MA, Richardson PG, Brandenburg N, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood. 2012;119:2764–2767.
- Thomas A, Mailankody S, Korde N, et al. Second malignancies after multiple myeloma: from 1960s to 2010s. Blood. 2012;119:2731–2737.
- Komrokji RS, Lancet JE, Swern AS, et al. Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. Blood. 2012;120:3419–3424.
- Sekeres MA, Gundacker H, Lancet J, et al. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. Blood. 2011;118:523–528.
- Chen Y, Kantarjian H, Estrov Z, et al. A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. Clin Lymph Myel Leuk. 2012;12:341–344.
- Cortes J, O’Brien S, Kantarjian H, et al. Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes. Leukemia. 1994;8:2174–2178.
- Joannides M, Grimwade D. Molecular biology of therapy-related leukaemias. Clin Transl Oncol. 2010;12:8–14.
- Oka S, Ono K, Nohgawa M. Myelodysplastic syndrome with concomitant del(5q) and JAK2 V61F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomide. Leuk Lymph. 2017;10:2511–2513.
- Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymph. 2013;54:683–687.
- Dimopoulos MA, Swenn AS, Li JS, et al. Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Cancer J. 2014;4:e257.
- Ferreri AJM, Sassone M, Zaja F, et al. Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single arm, multicentre phase 2 trial. Lancet Haematol. 2017;4:e137–e146.